Guardant Health, Inc. (GH)

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
United States Revenue	1.01B	923.28M	697.16M
United States Revenue Growth	9.86%	32.43%	32.41%
International Revenue	65.92M	58.74M	41.85M
International Revenue Growth	12.21%	40.35%	11.84%
Revenue (Other)	4.00K	-	-
Revenue (Total)	1.08B	982.02M	739.02M
Revenue (Total) Growth	10.00%	32.88%	31.04%

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Oncology Revenue	737.99M	683.60M	542.83M
Oncology Revenue Growth	7.96%	25.93%	34.40%
Biopharma and Data Revenue	217.73M	210.13M	177.58M
Biopharma and Data Revenue Growth	3.62%	18.33%	30.24%
Screening Revenue	115.65M	79.73M	5.12M
Screening Revenue Growth	45.04%	1456.05%	-
Licensing and Other Revenue	8.85M	8.56M	13.49M
Licensing and Other Revenue Growth	3.33%	-36.51%	-43.15%
Revenue (Other)	5.00K	-	-
Revenue (Total)	1.08B	982.02M	739.02M
Revenue (Total) Growth	10.00%	32.88%	31.04%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Precision Oncology Testing Revenue	-	-	687.94M
Precision Oncology Testing Revenue Growth	-	-	33.77%
Development Services and Other Revenue	-	-	51.08M
Development Services and Other Revenue Growth	-	-	2.78%
Revenue (Total)	1.08B	982.02M	739.02M
Revenue (Total) Growth	10.00%	32.88%	31.04%

Gross Profit

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Precision Oncology Testing Gross Profit	-	-	427.36M
Precision Oncology Testing Gross Profit Growth	-	-	38.43%
Development Services and Other Gross Profit	-	-	21.86M
Development Services and Other Gross Profit Growth	-	-	-22.41%
Gross Profit (Total)	701.01M	633.01M	449.22M
Gross Profit (Total) Growth	10.74%	40.91%	33.34%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Clinical Test Sales Volume	303.00K	276.00K	206.70K
Clinical Test Sales Volume Growth	9.78%	33.53%	19.55%
Biopharmaceutical Test Sales Volume	-	-	40.50K
Biopharmaceutical Test Sales Volume Growth	-	-	35.45%

Data Source: Fiscal.ai Last updated: May 7, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 18, 2026

Data Sources Report a data error